Skip to main content
Erschienen in: Current Geriatrics Reports 1/2022

12.02.2022 | Cardiovascular Disease in the Elderly (M Chen, Section Editor)

Amyloid Cardiomyopathy in Older Adults

verfasst von: Priyanka T. Bhattacharya, Mathew S. Maurer, Dia A. Smiley

Erschienen in: Current Geriatrics Reports | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Wild type transthyretin cardiac amyloidosis (ATTRwt, formerly called senile cardiac amyloidosis) is almost exclusively a disorder of adults over 60 years old and represents a quintessential type of diastolic heart failure in the older adult population. Cardiac amyloidosis is an infiltrative/restrictive cardiomyopathy that causes heart failure, atrial and ventricular arrhythmias, and conduction disease, and is associated with significant morbidity and mortality. Early suspicion by geriatricians including clinical clues or suggestive features when coupled with non-invasive cardiac testing that delineates a discordance between the wall thickness on echocardiography and the voltage on an electrocardiogram along with other suggestive findings on imaging of cardiac amyloidosis is paramount because early treatment can significantly improve prognosis.

Recent Findings

With the advent of a non-invasive method to diagnose ATTRwt without a biopsy and the development of effective therapies, there is an increasing interest in this condition.

Summary

The goal of this review is to provide clinical and testing guides and pearls, for early suspicion and detection, and subsequent referral to specialist cardiologists and amyloid specialists for further management and treatment.
Literatur
1.
Zurück zum Zitat Kittleson MM, et al. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation. 2020;142(1):e7–22.PubMedCrossRef Kittleson MM, et al. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation. 2020;142(1):e7–22.PubMedCrossRef
2.
Zurück zum Zitat Gillmore JD, et al. Guidelines on the diagnosis and investigation of AL amyloidosis. Br J Haematol. 2015;168(2):207–18.PubMedCrossRef Gillmore JD, et al. Guidelines on the diagnosis and investigation of AL amyloidosis. Br J Haematol. 2015;168(2):207–18.PubMedCrossRef
3.
Zurück zum Zitat Dubrey SW, Hawkins PN, Falk RH. Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart. 2011;97(1):75–84.PubMedCrossRef Dubrey SW, Hawkins PN, Falk RH. Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart. 2011;97(1):75–84.PubMedCrossRef
4.
Zurück zum Zitat Grogan M, Dispenzieri A. Natural history and therapy of AL cardiac amyloidosis. Heart Fail Rev. 2015;20(2):155–62.PubMedCrossRef Grogan M, Dispenzieri A. Natural history and therapy of AL cardiac amyloidosis. Heart Fail Rev. 2015;20(2):155–62.PubMedCrossRef
5.
Zurück zum Zitat González-López E, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585–94.CrossRefPubMed González-López E, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585–94.CrossRefPubMed
6.
Zurück zum Zitat Mohammed SF, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2014;2(2):113–22.PubMedPubMedCentralCrossRef Mohammed SF, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2014;2(2):113–22.PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Castano A, et al. Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis. JAMA Cardiol. 2016;1(8):880–9.PubMedCrossRef Castano A, et al. Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis. JAMA Cardiol. 2016;1(8):880–9.PubMedCrossRef
8.
Zurück zum Zitat Rapezzi C, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120(13):1203–12.PubMedCrossRef Rapezzi C, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120(13):1203–12.PubMedCrossRef
9.
Zurück zum Zitat Maurer MS, et al. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016;68(2):161–72.PubMedPubMedCentralCrossRef Maurer MS, et al. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016;68(2):161–72.PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat González-López E, et al. Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths. Eur Heart J. 2017;38(24):1895–904.PubMedCrossRef González-López E, et al. Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths. Eur Heart J. 2017;38(24):1895–904.PubMedCrossRef
11.
Zurück zum Zitat Connors LH, et al. Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin: A Prospective. Observational Cohort Study Circulation. 2016;133(3):282–90.PubMed Connors LH, et al. Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin: A Prospective. Observational Cohort Study Circulation. 2016;133(3):282–90.PubMed
13.
Zurück zum Zitat Sperry BW, et al. Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release. J Am Coll Cardiol. 2018;72(17):2040–50.PubMedCrossRef Sperry BW, et al. Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release. J Am Coll Cardiol. 2018;72(17):2040–50.PubMedCrossRef
14.
15.
16.
Zurück zum Zitat Hassan W, et al. Amyloid heart disease. New frontiers and insights in pathophysiology, diagnosis, and management. Tex Heart Inst J. 2005;32(2):178–84. Hassan W, et al. Amyloid heart disease. New frontiers and insights in pathophysiology, diagnosis, and management. Tex Heart Inst J. 2005;32(2):178–84.
18.
Zurück zum Zitat Quarta CC, et al. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation. 2014;129(18):1840–9.PubMedCrossRef Quarta CC, et al. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation. 2014;129(18):1840–9.PubMedCrossRef
20.
Zurück zum Zitat •• Maurer MS, et al. Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation. 2017;135(14):1357–77. This is a very imporant article answering common clinical questions and scenarios in the diagnosis and management of cardiac amyloidosis in general, which is beneficial for physicians.PubMedPubMedCentralCrossRef •• Maurer MS, et al. Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation. 2017;135(14):1357–77. This is a very imporant article answering common clinical questions and scenarios in the diagnosis and management of cardiac amyloidosis in general, which is beneficial for physicians.PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Di Bella G, et al. Usefulness of Combining Electrocardiographic and Echocardiographic Findings and Brain Natriuretic Peptide in Early Detection of Cardiac Amyloidosis in Subjects With Transthyretin Gene Mutation. Am J Cardiol. 2015;116(7):1122–7.PubMedCrossRef Di Bella G, et al. Usefulness of Combining Electrocardiographic and Echocardiographic Findings and Brain Natriuretic Peptide in Early Detection of Cardiac Amyloidosis in Subjects With Transthyretin Gene Mutation. Am J Cardiol. 2015;116(7):1122–7.PubMedCrossRef
22.
Zurück zum Zitat Carroll JD, Gaasch WH, McAdam KP. Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. Am J Cardiol. 1982;49(1):9–13.PubMedCrossRef Carroll JD, Gaasch WH, McAdam KP. Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. Am J Cardiol. 1982;49(1):9–13.PubMedCrossRef
23.
Zurück zum Zitat Martinez-Naharro A, et al. Magnetic Resonance in Transthyretin Cardiac Amyloidosis. J Am Coll Cardiol. 2017;70(4):466–77.PubMedCrossRef Martinez-Naharro A, et al. Magnetic Resonance in Transthyretin Cardiac Amyloidosis. J Am Coll Cardiol. 2017;70(4):466–77.PubMedCrossRef
24.
Zurück zum Zitat Fontana M, Martinez-Naharro A, Hawkins PN. Staging Cardiac Amyloidosis With CMR: Understanding the Different Phenotypes. JACC Cardiovasc Imaging. 2016;9(11):1278–9.PubMedCrossRef Fontana M, Martinez-Naharro A, Hawkins PN. Staging Cardiac Amyloidosis With CMR: Understanding the Different Phenotypes. JACC Cardiovasc Imaging. 2016;9(11):1278–9.PubMedCrossRef
25.
Zurück zum Zitat Fontana M, et al. Cardiovascular magnetic resonance for amyloidosis. Heart Fail Rev. 2015;20(2):133–44.PubMedCrossRef Fontana M, et al. Cardiovascular magnetic resonance for amyloidosis. Heart Fail Rev. 2015;20(2):133–44.PubMedCrossRef
26.
Zurück zum Zitat Di Giovanni B, Gustafson D, Delgado DH. Amyloid transthyretin cardiac amyloidosis: diagnosis and management. Expert Rev Cardiovasc Ther. 2019;17(9):673–81.PubMedCrossRef Di Giovanni B, Gustafson D, Delgado DH. Amyloid transthyretin cardiac amyloidosis: diagnosis and management. Expert Rev Cardiovasc Ther. 2019;17(9):673–81.PubMedCrossRef
27.
Zurück zum Zitat Carvalho FP, Erthal F, Azevedo CF. The Role of Cardiac MR Imaging in the Assessment of Patients with Cardiac Amyloidosis. Magn Reson Imaging Clin N Am. 2019;27(3):453–63.PubMedCrossRef Carvalho FP, Erthal F, Azevedo CF. The Role of Cardiac MR Imaging in the Assessment of Patients with Cardiac Amyloidosis. Magn Reson Imaging Clin N Am. 2019;27(3):453–63.PubMedCrossRef
28.
Zurück zum Zitat Falk RH, et al. AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. J Am Coll Cardiol. 2016;68(12):1323–41.PubMedCrossRef Falk RH, et al. AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. J Am Coll Cardiol. 2016;68(12):1323–41.PubMedCrossRef
29.
Zurück zum Zitat Nativi-Nicolau J, Maurer MS. Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types. Curr Opin Cardiol. 2018;33(5):571–9.PubMedCrossRef Nativi-Nicolau J, Maurer MS. Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types. Curr Opin Cardiol. 2018;33(5):571–9.PubMedCrossRef
30.
Zurück zum Zitat Kyriakou P, et al. Diagnosis of cardiac amyloidosis: a systematic review on the role of imaging and biomarkers. BMC Cardiovasc Disord. 2018;18(1):221.PubMedPubMedCentralCrossRef Kyriakou P, et al. Diagnosis of cardiac amyloidosis: a systematic review on the role of imaging and biomarkers. BMC Cardiovasc Disord. 2018;18(1):221.PubMedPubMedCentralCrossRef
31.
32.
Zurück zum Zitat Gillmore JD, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016;133(24):2404–12.PubMedCrossRef Gillmore JD, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016;133(24):2404–12.PubMedCrossRef
33.
Zurück zum Zitat Bokhari S, et al. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6(2):195–201.PubMedPubMedCentralCrossRef Bokhari S, et al. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6(2):195–201.PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Glaudemans AW, et al. Bone scintigraphy with (99m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis. Amyloid. 2014;21(1):35–44.PubMedCrossRef Glaudemans AW, et al. Bone scintigraphy with (99m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis. Amyloid. 2014;21(1):35–44.PubMedCrossRef
35.
Zurück zum Zitat Fontana M, et al. Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging. 2014;7(2):157–65.PubMedCrossRef Fontana M, et al. Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging. 2014;7(2):157–65.PubMedCrossRef
36.
Zurück zum Zitat Castaño A, Bokhari S, Maurer MS. Unveiling wild-type transthyretin cardiac amyloidosis as a significant and potentially modifiable cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2595–7.PubMedCrossRef Castaño A, Bokhari S, Maurer MS. Unveiling wild-type transthyretin cardiac amyloidosis as a significant and potentially modifiable cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2595–7.PubMedCrossRef
37.
Zurück zum Zitat Maurer MS, et al. Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. Circ Heart Fail. 2019;12(9):e006075. Maurer MS, et al. Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. Circ Heart Fail. 2019;12(9):e006075.
38.
Zurück zum Zitat Ansari-Lari MA, Ali SZ. Fine-needle aspiration of abdominal fat pad for amyloid detection: a clinically useful test? Diagn Cytopathol. 2004;30(3):178–81.PubMedCrossRef Ansari-Lari MA, Ali SZ. Fine-needle aspiration of abdominal fat pad for amyloid detection: a clinically useful test? Diagn Cytopathol. 2004;30(3):178–81.PubMedCrossRef
39.
Zurück zum Zitat Fine NM, et al. Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis. Am J Cardiol. 2014;113(10):1723–7.PubMedCrossRef Fine NM, et al. Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis. Am J Cardiol. 2014;113(10):1723–7.PubMedCrossRef
40.
41.
Zurück zum Zitat Ritts AJ, et al. Current Concepts of Cardiac Amyloidosis: Diagnosis, Clinical Management, and the Need for Collaboration. Heart Fail Clin. 2017;13(2):409–16.PubMedCrossRef Ritts AJ, et al. Current Concepts of Cardiac Amyloidosis: Diagnosis, Clinical Management, and the Need for Collaboration. Heart Fail Clin. 2017;13(2):409–16.PubMedCrossRef
42.
Zurück zum Zitat Pollak A, Falk RH. Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis. Chest. 1993;104(2):618–20.PubMedCrossRef Pollak A, Falk RH. Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis. Chest. 1993;104(2):618–20.PubMedCrossRef
43.
Zurück zum Zitat Gertz MA, et al. Selective binding of nifedipine to amyloid fibrils. Am J Cardiol. 1985;55(13 Pt 1):1646.PubMedCrossRef Gertz MA, et al. Selective binding of nifedipine to amyloid fibrils. Am J Cardiol. 1985;55(13 Pt 1):1646.PubMedCrossRef
44.
Zurück zum Zitat Bozkurt B, et al. Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association. Circulation. 2016;134(23):e579–646.PubMed Bozkurt B, et al. Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association. Circulation. 2016;134(23):e579–646.PubMed
45.
Zurück zum Zitat Longhi S, et al. Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role. Amyloid. 2015;22(3):147–55.PubMedCrossRef Longhi S, et al. Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role. Amyloid. 2015;22(3):147–55.PubMedCrossRef
46.
Zurück zum Zitat Barbhaiya CR, et al. Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy. Heart Rhythm. 2016;13(2):383–90.PubMedCrossRef Barbhaiya CR, et al. Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy. Heart Rhythm. 2016;13(2):383–90.PubMedCrossRef
47.
Zurück zum Zitat Priori SG, et al. 2015ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793–2867. Priori SG, et al. 2015ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793–2867.
49.
Zurück zum Zitat Gregoratos G, et al. ACC/AHA Guidelines for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices: Executive Summary–a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Pacemaker Implantation). Circulation. 1998;97(13):1325–35.PubMedCrossRef Gregoratos G, et al. ACC/AHA Guidelines for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices: Executive Summary–a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Pacemaker Implantation). Circulation. 1998;97(13):1325–35.PubMedCrossRef
50.
Zurück zum Zitat Bulawa CE, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A. 2012;109(24):9629–34.PubMedPubMedCentralCrossRef Bulawa CE, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A. 2012;109(24):9629–34.PubMedPubMedCentralCrossRef
51.
Zurück zum Zitat Maurer MS, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018;379(11):1007–16.PubMedCrossRef Maurer MS, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018;379(11):1007–16.PubMedCrossRef
52.
Zurück zum Zitat Rosenblum H, et al. TTR (Transthyretin) Stabilizers Are Associated With Improved Survival in Patients With TTR Cardiac Amyloidosis. Circ Heart Fail. 2018;11(4):e004769. Rosenblum H, et al. TTR (Transthyretin) Stabilizers Are Associated With Improved Survival in Patients With TTR Cardiac Amyloidosis. Circ Heart Fail. 2018;11(4):e004769.
54.
Zurück zum Zitat Adams D, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018;379(1):11–21.PubMedCrossRef Adams D, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018;379(1):11–21.PubMedCrossRef
55.
Zurück zum Zitat Benson MD, et al. Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy. Amyloid. 2017;24(4):219–25.PubMedCrossRef Benson MD, et al. Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy. Amyloid. 2017;24(4):219–25.PubMedCrossRef
56.
Zurück zum Zitat Palladini G, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015;126(5):612–5.PubMedCrossRef Palladini G, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015;126(5):612–5.PubMedCrossRef
57.
Zurück zum Zitat Palladini G, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 2020;136(1):71–80.PubMedPubMedCentralCrossRef Palladini G, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 2020;136(1):71–80.PubMedPubMedCentralCrossRef
58.
Zurück zum Zitat Kastritis E, Dimopoulos MA. Prognosis and risk assessment in AL amyloidosis–state of the art. Amyloid. 2011;18(Suppl 1):89–91.PubMedCrossRef Kastritis E, Dimopoulos MA. Prognosis and risk assessment in AL amyloidosis–state of the art. Amyloid. 2011;18(Suppl 1):89–91.PubMedCrossRef
59.
Zurück zum Zitat Jaccard A, et al. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). Haematologica. 2014;99(9):1479–85.PubMedPubMedCentralCrossRef Jaccard A, et al. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). Haematologica. 2014;99(9):1479–85.PubMedPubMedCentralCrossRef
60.
Zurück zum Zitat Palladini G, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation. 2003;107(19):2440–5.PubMedCrossRef Palladini G, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation. 2003;107(19):2440–5.PubMedCrossRef
61.
Zurück zum Zitat Kristen AV, et al. Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay. Blood. 2010;116(14):2455–61.PubMedCrossRef Kristen AV, et al. Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay. Blood. 2010;116(14):2455–61.PubMedCrossRef
62.
Zurück zum Zitat Kumar S, et al. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood. 2010;116(24):5126–9.PubMedPubMedCentralCrossRef Kumar S, et al. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood. 2010;116(24):5126–9.PubMedPubMedCentralCrossRef
63.
Zurück zum Zitat Milani P, et al. Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome. Blood. 2017;130(5):625–31.PubMedCrossRef Milani P, et al. Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome. Blood. 2017;130(5):625–31.PubMedCrossRef
64.
Zurück zum Zitat Kumar S, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989–95.PubMedPubMedCentralCrossRef Kumar S, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989–95.PubMedPubMedCentralCrossRef
65.
Zurück zum Zitat Wechalekar AD, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121(17):3420–7.PubMedCrossRef Wechalekar AD, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121(17):3420–7.PubMedCrossRef
66.
Zurück zum Zitat Palladini G, et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood. 2010;116(18):3426–30.PubMedCrossRef Palladini G, et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood. 2010;116(18):3426–30.PubMedCrossRef
67.
Zurück zum Zitat Sidana S, et al. Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis. Mayo Clin Proc. 2019;94(3):455–64.PubMed Sidana S, et al. Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis. Mayo Clin Proc. 2019;94(3):455–64.PubMed
68.
Zurück zum Zitat Rapezzi C, et al. Phenotypic and genotypic heterogeneity in transthyretin-related cardiac amyloidosis: towards tailoring of therapeutic strategies? Amyloid. 2006;13(3):143–53.PubMedCrossRef Rapezzi C, et al. Phenotypic and genotypic heterogeneity in transthyretin-related cardiac amyloidosis: towards tailoring of therapeutic strategies? Amyloid. 2006;13(3):143–53.PubMedCrossRef
69.
Zurück zum Zitat Green CP, et al. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000;35(5):1245–55.PubMedCrossRef Green CP, et al. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000;35(5):1245–55.PubMedCrossRef
70.
Zurück zum Zitat Pettersen KI, et al. Reliability and validity of the Kansas City cardiomyopathy questionnaire in patients with previous myocardial infarction. Eur J Heart Fail. 2005;7(2):235–42.PubMedCrossRef Pettersen KI, et al. Reliability and validity of the Kansas City cardiomyopathy questionnaire in patients with previous myocardial infarction. Eur J Heart Fail. 2005;7(2):235–42.PubMedCrossRef
71.
Zurück zum Zitat Grogan M, et al. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. J Am Coll Cardiol. 2016;68(10):1014–20.PubMedCrossRef Grogan M, et al. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. J Am Coll Cardiol. 2016;68(10):1014–20.PubMedCrossRef
72.
Zurück zum Zitat Gillmore JD, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39(30):2799–806.PubMedCrossRef Gillmore JD, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39(30):2799–806.PubMedCrossRef
Metadaten
Titel
Amyloid Cardiomyopathy in Older Adults
verfasst von
Priyanka T. Bhattacharya
Mathew S. Maurer
Dia A. Smiley
Publikationsdatum
12.02.2022
Verlag
Springer US
Erschienen in
Current Geriatrics Reports / Ausgabe 1/2022
Elektronische ISSN: 2196-7865
DOI
https://doi.org/10.1007/s13670-022-00374-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.